Condition
Malignant Mesothelioma
Estimated Enrollment: 840
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Randomized|Primary Purpose: Treatment
Study ID Numbers: BTS-MRC-MS01|CDR0000347461|ISRCTN54469112|EU-20349
Study First Received: January 9, 2004
Last Updated: August 6, 2013
Estimated Primary Completion Date: null
Primary Outcome Measures:
Overall survival|Palliation of chest pain, breathlessness, malaise (e.g., feeling weak, tiredness, anorexia), and sweating attacks|Performance status as measured by WHO grade|Analgesic usage|Toxicity as measured by the NCIC CTC|Quality of life as assessed by the European Organization for Research and Treatment of Cancer|Tumor response as measured by the RECIST criteria|Progression-free survival as measured by CT scan
Sponsors and Collaborators:
Medical Research Council|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00075699
